World's Best Scientists 2026 revealed!
Lisa Licitra

Lisa Licitra

D-Index & Metrics

Medicine

D-Index
92
Citations
41509
World Ranking
11121
National Ranking
403

Overview

Lisa Licitra is affiliated with the University of Milan in Italy, where their research primarily focuses on medical studies within the field of oncology. Their work spans multiple subfields including otorhinolaryngology, pulmonary and respiratory medicine, surgery, and radiology, nuclear medicine, and imaging.

The scope of their research covers several main topics:

  • Head and Neck Cancer Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Diagnosis and Treatment
  • Salivary Gland Tumors Diagnosis and Treatment
  • Ear and Head Tumors

Lisa Licitra has contributed to numerous scientific publications, with recent papers including:

  • Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2020, Annals of Oncology
  • Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2020, Annals of Oncology
  • Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study, 2020, Annals of Oncology
  • Management of Salivary Gland Malignancy: ASCO Guideline, 2021, Journal of Clinical Oncology
  • Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group, 2021, Radiotherapy and Oncology

Licitra frequently publishes in several key venues related to oncology and clinical medicine, notably:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Radiotherapy and Oncology
  • Oral Oncology
  • European Journal of Cancer

Their collaborative network includes several frequent co-authors such as:

  • Stefano Cavalieri
  • Paolo Bossi
  • Ester Orlandi
  • Carlo Resteghini
  • Salvatore Alfieri

Lisa Licitra's body of work encompasses a substantial number of publications in medicine, amounting to over 600 contributions, with oncology-related publications making up a significant portion. Their research addresses clinical practice guidelines, treatment strategies, and the development of new approaches in cancer immunotherapy and diagnostics focused on head and neck malignancies as well as respiratory cancers.

Best Publications

  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

    Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  • Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    Ezra E W Cohen;Denis Soulières;Christophe Le Tourneau;Christophe Le Tourneau;Christophe Le Tourneau;José Dinis

  • Cabozantinib in Progressive Medullary Thyroid Cancer

    Rossella Elisei;Martin J. Schlumberger;Stefan P. Müller;Patrick Schöffski

  • Rare cancers are not so rare: The rare cancer burden in Europe

    Gemma Gatta;Jan Maarten van der Zwan;Paolo G Casali;Sabine Siesling

  • High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma

    Lisa Licitra;Federica Perrone;Paolo Bossi;Simona Suardi

  • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

    Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay

  • Squamous cell carcinoma of the head and neck : EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Vincent Grégoire;J-L Lefebvre;L Licitra;E Felip

  • Major and minor salivary gland tumors

    Marco Guzzo;Laura D. Locati;Franz J. Prott;Gemma Gatta

  • Motesanib diphosphate in progressive differentiated thyroid cancer.

    Steven I. Sherman;Lori J. Wirth;Jean Pierre Droz;Michael Hofmann

  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

    Ezra E.W. Cohen;R. Bryan Bell;Carlo B. Bifulco;Barbara Burtness

  • Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

    Jan B Vermorken;Jan Stöhlmacher-Williams;Irina Davidenko;Lisa Licitra

  • Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    J.-P. Machiels;J.-P. Machiels;C. René Leemans;W. Golusinski;C. Grau

  • Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s : the EUROCARE-5 population-based study

    Gemma Gatta;Laura Botta;María José Sánchez;Lesley Ann Anderson

  • Reprint of "Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up"

    J.-P. Machiels;C. René Leemans;W. Golusinski;C. Grau

  • Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    Jean Pascal H Machiels;Robert I. Haddad;Jérôme Fayette;Lisa F. Licitra

  • Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

    Kevin J Harrington;Robert L Ferris;George Blumenschein;A Dimitrios Colevas

  • Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

    J. Simon W. Stewart;Ezra E.W. Cohen;Lisa Licitra;Carla M.L. Van Herpen

  • Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers

    Scott A. Laurie;Lisa Licitra

  • Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy

    J.L. Lefebvre;F. Rolland;M. Tesselaar;E. Bardet

Frequent Co-Authors

Kevin J. Harrington
Kevin J. Harrington Royal Marsden NHS Foundation Trust
Robert I. Haddad
Robert I. Haddad Harvard University
Ezra E.W. Cohen
Ezra E.W. Cohen University of California, San Diego
Jan B. Vermorken
Jan B. Vermorken University of Antwerp
Robert L. Ferris
Robert L. Ferris University of Pittsburgh
Silvana Pilotti
Silvana Pilotti University of Milan
Silvana Canevari
Silvana Canevari University of Milan
Maura L. Gillison
Maura L. Gillison The University of Texas MD Anderson Cancer Center
Paolo G. Casali
Paolo G. Casali University of Milan
Everett E. Vokes
Everett E. Vokes University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary healthcare degrees online can be a smart choice for those pursuing a career in medicine or related fields. Many students are seeking affordable routes to advanced qualifications, such as the least expensive dnp programs, which open pathways for leadership roles in nursing without breaking the bank.

Pharmacy is another high-demand field with remote learning options. Earning your credentials through a flexible online pharmd program allows you to train as a pharmacist while balancing other commitments.

If you’re interested in the digital and administrative side of healthcare, consider accredited him programs (Health Information Management) that focus on managing medical data and technology in clinical settings.

Additionally, those seeking quick entry into the medical field may benefit from the cheapest medical coding certification online, which can lead to jobs in billing, coding, and health records.

These online degrees and certifications provide practical, affordable alternatives for launching or advancing your healthcare career in the USA.

Best Scientists Citing Lisa Licitra

Trending Scientists

Recently Published Articles